Kelly Graham Ural
Kelly Graham Ural has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
George Gilly
Ochsner Clinic Foundation, New Orleans, LA, USA
2 shared publicationsHeather Scuderi-Porter
Ochsner Clinic Foundation, New Orleans, LA, USA
2 shared publicationsJacqueline Volpi-Abadie
Ochsner Clinic Foundation, New Orleans, LA, USA
2 shared publicationsJay E. Trusheim
Ochsner Clinic Foundation
2 shared publicationsAllison L. Egger
Ochsner Clinic Foundation, New Orleans, LA, USA
1 shared publicationAmanda Vining
Ochsner Clinic Foundation
1 shared publication
Latest Publications
- 8 November 2025
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 40 (2) , 460-461
Viscoelastic Hemostatic Assays and the Pursuit of Universal Adoption in Cardiac Surgery
- 8 November 2025
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 40 (2) , 460-461
Viscoelastic Hemostatic Assays and the Pursuit of Universal Adoption in Cardiac Surgery
- Open Access
- 4 April 2025
- Published by Ochsner Journal in Ochsner Journal
- Vol. 25 (2) , 148-150
Bilateral Hypoglossal Nerve Palsy After Cardiac Surgery
Background Hypoglossal nerve palsy is a rare perioperative complication caused by excessive stretching of the nerve. Symptoms include tongue deviation, dysarthria, hoarseness, and dysphagia. We present the case of a patient who experienced bilateral hypoglossal nerve palsy after cardiac surgery. Case Report A 68-year-old male with hypertension, sleep apnea, and aortic insufficiency presented for aortic valve replacement. He was easily intubated using video laryngoscopy, and surgery proceeded without incident. He remained intubated overnight and was extubated on postoperative day 1. Initially, hoarseness and tongue edema were noted. Further evaluation revealed oropharyngeal dysphagia, silent aspiration, and inability to protrude the tongue, all consistent with a bilateral hypoglossal nerve injury. Because the patient was unable to swallow, a percutaneous endoscopic gastrostomy (PEG) tube was placed. Three months later, electromyography showed denervation of the tongue, suggestive of hypoglossal nerve injury, with good prognosis for recovery. The PEG tube was removed, and the patient was able to tolerate a soft diet. Eight months postoperatively, the patient was started on a normal diet, and at 18 months postoperatively, his speech and vocal fatigue had improved to approximately 90% of normal. Conclusion Although rare, hypoglossal nerve palsy is a perioperative complication that can have deleterious effects on patient well-being. Most cases are self-limited and resolve completely in 4 to 6 months; however, some patients experience more lasting effects. Anesthesiologists should take appropriate precautions when positioning a patient9s head and neck during intubation and throughout the duration of surgery to help prevent hypoglossal nerve injury.
- 4 April 2025
- Published by Ochsner Journal in Ochsner Journal
- Vol. 25 (2) , 148-150
Open AccessBilateral Hypoglossal Nerve Palsy After Cardiac Surgery
Background Hypoglossal nerve palsy is a rare perioperative complication caused by excessive stretching of the nerve. Symptoms include tongue deviation, dysarthria, hoarseness, and dysphagia. We present the case of a patient who experienced bilateral hypoglossal nerve palsy after cardiac surgery. Case Report A 68-year-old male with hypertension, sleep apnea, and aortic insufficiency presented for aortic valve replacement. He was easily intubated using video laryngoscopy, and surgery proceeded without incident. He remained intubated overnight and was extubated on postoperative day 1. Initially, hoarseness and tongue edema were noted. Further evaluation revealed oropharyngeal dysphagia, silent aspiration, and inability to protrude the tongue, all consistent with a bilateral hypoglossal nerve injury. Because the patient was unable to swallow, a percutaneous endoscopic gastrostomy (PEG) tube was placed. Three months later, electromyography showed denervation of the tongue, suggestive of hypoglossal nerve injury, with good prognosis for recovery. The PEG tube was removed, and the patient was able to tolerate a soft diet. Eight months postoperatively, the patient was started on a normal diet, and at 18 months postoperatively, his speech and vocal fatigue had improved to approximately 90% of normal. Conclusion Although rare, hypoglossal nerve palsy is a perioperative complication that can have deleterious effects on patient well-being. Most cases are self-limited and resolve completely in 4 to 6 months; however, some patients experience more lasting effects. Anesthesiologists should take appropriate precautions when positioning a patient9s head and neck during intubation and throughout the duration of surgery to help prevent hypoglossal nerve injury.
- 7 November 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 67-72
Use of a New Standardized Unfractionated Heparin Protocol for Left-Sided Ablation Procedures Improves Time in the Therapeutic ACT Range
- 7 November 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 67-72
Use of a New Standardized Unfractionated Heparin Protocol for Left-Sided Ablation Procedures Improves Time in the Therapeutic ACT Range
- Open Access
- 8 August 2023
- Published by Ochsner Journal in Ochsner Journal
- Vol. 23 (4) , 363-366
Dexmedetomidine Used to Maintain Spontaneous Ventilation in a Patient With Anterior Mediastinal Mass and Superior Vena Cava Syndrome
Background: Anterior mediastinal masses (AMMs), which can be benign or malignant, are a common cause of superior vena cava (SVC) syndrome. Because of their location, AMMs can cause significant airway compromise during the perioperative period, so anesthetic management of a patient with SVC syndrome can present significant challenges. Case Report: A patient presented with SVC syndrome secondary to a large AMM. After careful consideration and discussion with the patient about the risks and benefits of various approaches, the decision was made to provide sedation using dexmedetomidine as the sole agent during image-guided biopsy. Conclusion: Patients who present with AMMs require careful anesthetic planning. Dexmedetomidine can be effective in achieving the primary objective of maintaining spontaneous respiration.
- 8 August 2023
- Published by Ochsner Journal in Ochsner Journal
- Vol. 23 (4) , 363-366
Open AccessDexmedetomidine Used to Maintain Spontaneous Ventilation in a Patient With Anterior Mediastinal Mass and Superior Vena Cava Syndrome
Background: Anterior mediastinal masses (AMMs), which can be benign or malignant, are a common cause of superior vena cava (SVC) syndrome. Because of their location, AMMs can cause significant airway compromise during the perioperative period, so anesthetic management of a patient with SVC syndrome can present significant challenges. Case Report: A patient presented with SVC syndrome secondary to a large AMM. After careful consideration and discussion with the patient about the risks and benefits of various approaches, the decision was made to provide sedation using dexmedetomidine as the sole agent during image-guided biopsy. Conclusion: Patients who present with AMMs require careful anesthetic planning. Dexmedetomidine can be effective in achieving the primary objective of maintaining spontaneous respiration.
- 16 December 2022
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (4) , 657-658
Reverse Takotsubo Cardiomyopathy During Liver Transplantation: Expert Commentary
- 16 December 2022
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 37 (4) , 657-658
Reverse Takotsubo Cardiomyopathy During Liver Transplantation: Expert Commentary
- Open Access
- 15 March 2021
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 53 (1) , 46-49
Antiphospholipid Syndrome and Cardiac Bypass: The Careful Balance between Clotting and Bleeding
Antiphospholipid syndrome (APS) is an acquired autoimmune condition characterized by the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibody, and anti-β2 glycoprotein-I antibody) which leads to clinical thrombosis via a multifactorial mechanism of action. Despite the propensity to form clot in vivo, these antibodies interfere with the assembly of the prothrombinase complex on phospholipids in in vitro assays, leading to prolongation of activated clotting time and activated partial thromboplastin time. This disconnect between what occurs in vivo and in vitro makes monitoring anticoagulation during cardiac surgery particularly complex. We present a patient with APS undergoing coronary artery bypass grafting with cardiopulmonary bypass. We delineate our strategy for managing anticoagulation in the presence of this syndrome using the Hepcon Hemostasis Management System Plus (Medtronic, Inc. Minneapolis, MN) device by targeting whole blood heparin concentration to monitor anticoagulation.
- 15 March 2021
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 53 (1) , 46-49
Open AccessAntiphospholipid Syndrome and Cardiac Bypass: The Careful Balance between Clotting and Bleeding
Antiphospholipid syndrome (APS) is an acquired autoimmune condition characterized by the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibody, and anti-β2 glycoprotein-I antibody) which leads to clinical thrombosis via a multifactorial mechanism of action. Despite the propensity to form clot in vivo, these antibodies interfere with the assembly of the prothrombinase complex on phospholipids in in vitro assays, leading to prolongation of activated clotting time and activated partial thromboplastin time. This disconnect between what occurs in vivo and in vitro makes monitoring anticoagulation during cardiac surgery particularly complex. We present a patient with APS undergoing coronary artery bypass grafting with cardiopulmonary bypass. We delineate our strategy for managing anticoagulation in the presence of this syndrome using the Hepcon Hemostasis Management System Plus (Medtronic, Inc. Minneapolis, MN) device by targeting whole blood heparin concentration to monitor anticoagulation.
- 23 May 2018
- Published by SAGE Publications in Seminars in Cardiothoracic and Vascular Anesthesia
- Vol. 22 (4) , 353-358
Improved Cost-Effectiveness and Blood Product Utilization From Instituting a Blood Ordering Algorithm for Cardiac Surgical Cases
Background. Results of a previous study revealed an over-ordering of blood products for cardiac surgery and led to the creation of a new blood ordering algorithm. This follow-up study has been conducted to evaluate improvement in ordering practices. Methods. Retrospective data were collected for 171 patients who underwent coronary artery bypass grafting or valve surgery from March 2015 to March 2016 to determine the crossmatch-to-transfusion ratio (C:tx) and potential cost savings. Results were compared with pre-algorithm values and considered statistically significant if the 95% confidence interval did not include zero. Results. Prior to the algorithm, 100% of patients undergoing cardiac surgery were crossmatched. After instituting the algorithm, this decreased to 15%. The overall C:tx decreased from 7.97 to 2.14. Cost savings were calculated as $114.79 (coronary artery bypass grafting) and $129.05 (valve surgery) per patient. Conclusions. The creation of a new algorithm to guide ordering practices has significantly improved the C:tx, reduced unnecessary crossmatching, and lowered costs.
- 23 May 2018
- Published by SAGE Publications in Seminars in Cardiothoracic and Vascular Anesthesia
- Vol. 22 (4) , 353-358
Improved Cost-Effectiveness and Blood Product Utilization From Instituting a Blood Ordering Algorithm for Cardiac Surgical Cases
Background. Results of a previous study revealed an over-ordering of blood products for cardiac surgery and led to the creation of a new blood ordering algorithm. This follow-up study has been conducted to evaluate improvement in ordering practices. Methods. Retrospective data were collected for 171 patients who underwent coronary artery bypass grafting or valve surgery from March 2015 to March 2016 to determine the crossmatch-to-transfusion ratio (C:tx) and potential cost savings. Results were compared with pre-algorithm values and considered statistically significant if the 95% confidence interval did not include zero. Results. Prior to the algorithm, 100% of patients undergoing cardiac surgery were crossmatched. After instituting the algorithm, this decreased to 15%. The overall C:tx decreased from 7.97 to 2.14. Cost savings were calculated as $114.79 (coronary artery bypass grafting) and $129.05 (valve surgery) per patient. Conclusions. The creation of a new algorithm to guide ordering practices has significantly improved the C:tx, reduced unnecessary crossmatching, and lowered costs.
- 1 April 2018
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 32 (2) , 607-620
The Educational Evolution of Fellowship Training in Cardiothoracic Anesthesiology – Perspectives From Program Directors Around the United States
- 1 April 2018
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 32 (2) , 607-620
The Educational Evolution of Fellowship Training in Cardiothoracic Anesthesiology – Perspectives From Program Directors Around the United States
- 9 May 2017
- Published by SAGE Publications in Seminars in Cardiothoracic and Vascular Anesthesia
- Vol. 21 (4) , 345-351
Long-Term Cardiac Morbidity and Mortality in Patients With Aortic Valve Disease Following Liver Transplantation: A Case Matching Study
Introduction. This retrospective study examined the role of aortic valve (AV) disease in patients who underwent orthotopic liver transplantation (OLT) to determine the incidence of postoperative cardiac morbidity and mortality when compared with a matched control group without AV disease. Methods. Patients were included in the AV group if diagnosed with aortic stenosis (AS) or aortic regurgitation or had received AV replacement prior to OLT. The AV group (n = 53) was matched to a control group (n = 212) with the following preoperative variables: type of organ transplanted, age, gender, race, body mass index, MELD, redo-transplantation, preoperative renal replacement therapy, nonalcoholic steatohepatitis, viral hepatitis, diabetes, and coronary artery disease. A 1:4 ratio was utilized to improve the efficiency and power of the analysis. Results. No significant difference in survival or posttransplant cardiac complications (acute coronary syndrome, heart failure, or dysrhythmia) was observed between groups. However, statistically significantly more patients—11% (6/53)—required coronary intervention following OLT in the AV group, whereas 3% (7/212) required coronary intervention (χ2 = 5.8; P = .0156) in the control group. Following OLT, 9% (5/53) in the AV group required surgical or nonsurgical AV intervention, whereas no valvular events were observed in the control group. Event-free survival in the AV group, with an end point defined as AV intervention (n = 5) and death (n = 10), was 92% (49/53) at 1 year, 83% (44/53) at 3 years, and 72% (38/53) at 5 years. Conclusions. Patients with pretransplant AV replacement or AS have significant cardiac complications (myocardial infarction, AV replacement, or cardiac death) in 1 to 3 years post-OLT.
- 9 May 2017
- Published by SAGE Publications in Seminars in Cardiothoracic and Vascular Anesthesia
- Vol. 21 (4) , 345-351
Long-Term Cardiac Morbidity and Mortality in Patients With Aortic Valve Disease Following Liver Transplantation: A Case Matching Study
Introduction. This retrospective study examined the role of aortic valve (AV) disease in patients who underwent orthotopic liver transplantation (OLT) to determine the incidence of postoperative cardiac morbidity and mortality when compared with a matched control group without AV disease. Methods. Patients were included in the AV group if diagnosed with aortic stenosis (AS) or aortic regurgitation or had received AV replacement prior to OLT. The AV group (n = 53) was matched to a control group (n = 212) with the following preoperative variables: type of organ transplanted, age, gender, race, body mass index, MELD, redo-transplantation, preoperative renal replacement therapy, nonalcoholic steatohepatitis, viral hepatitis, diabetes, and coronary artery disease. A 1:4 ratio was utilized to improve the efficiency and power of the analysis. Results. No significant difference in survival or posttransplant cardiac complications (acute coronary syndrome, heart failure, or dysrhythmia) was observed between groups. However, statistically significantly more patients—11% (6/53)—required coronary intervention following OLT in the AV group, whereas 3% (7/212) required coronary intervention (χ2 = 5.8; P = .0156) in the control group. Following OLT, 9% (5/53) in the AV group required surgical or nonsurgical AV intervention, whereas no valvular events were observed in the control group. Event-free survival in the AV group, with an end point defined as AV intervention (n = 5) and death (n = 10), was 92% (49/53) at 1 year, 83% (44/53) at 3 years, and 72% (38/53) at 5 years. Conclusions. Patients with pretransplant AV replacement or AS have significant cardiac complications (myocardial infarction, AV replacement, or cardiac death) in 1 to 3 years post-OLT.